CrystalGenomics Inc (KQ:083790) — Market Cap & Net Worth
Market Cap & Net Worth: CrystalGenomics Inc (083790)
CrystalGenomics Inc (KQ:083790) has a market capitalization of $26.40 Million (₩38.96 Billion) as of September 18, 2026. Listed on the KQ stock exchange, this Korea-based company holds position #24269 globally and #1716 in its home market, demonstrating a 0.63% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying CrystalGenomics Inc's stock price ₩963.00 by its total outstanding shares 40452700 (40.45 Million). Also see how large is CrystalGenomics Inc's balance sheet for a full breakdown of the balance sheet.
CrystalGenomics Inc Market Cap History: 2015 to 2026
CrystalGenomics Inc's market capitalization history from 2015 to 2026. Data shows change from $196.14 Million to $26.40 Million (-15.74% CAGR). Also see CrystalGenomics Inc cash conversion from operations for how efficiently the company converts equity into cash flow.
Index Memberships
CrystalGenomics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
Kosdaq Composite Index
KOSDAQ
|
$233.34 Billion | 0.01% | #887 of 1384 |
|
Kosdaq Composite Index
KQ11
|
$233.34 Billion | 0.01% | #887 of 1384 |
Weight: CrystalGenomics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
CrystalGenomics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how CrystalGenomics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest CrystalGenomics Inc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.01x
CrystalGenomics Inc's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $196.14 Million | $6.14 Billion | -$4.85 Billion | 0.03x | N/A |
| 2016 | $234.81 Million | $14.52 Billion | -$2.18 Billion | 0.02x | N/A |
| 2017 | $328.05 Million | $12.18 Billion | -$8.58 Billion | 0.03x | N/A |
| 2018 | $316.18 Million | $13.89 Billion | $6.91 Billion | 0.02x | 0.05x |
| 2019 | $270.49 Million | $14.01 Billion | -$37.59 Billion | 0.02x | N/A |
| 2020 | $327.14 Million | $30.22 Billion | -$9.84 Billion | 0.01x | N/A |
| 2021 | $181.48 Million | $42.38 Billion | -$15.90 Billion | 0.00x | N/A |
| 2022 | $95.95 Million | $4.32 Billion | -$23.87 Billion | 0.02x | N/A |
| 2023 | $76.07 Million | $4.88 Billion | -$48.92 Billion | 0.02x | N/A |
| 2024 | $65.93 Million | $7.25 Billion | -$51.54 Billion | 0.01x | N/A |
Competitor Companies of 083790 by Market Capitalization
Companies near CrystalGenomics Inc in the global market cap rankings as of September 18, 2026. Review 083790 intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to CrystalGenomics Inc by market ranking:
- Sam Chun Dang Pharm. Co. Ltd (KQ:000250): Ranked #5752 globally with a market cap of $2.26 Billion USD ( ₩3.34 Trillion KRW).
- ST Pharm Co.Ltd (KQ:237690): Ranked #8322 globally with a market cap of $1.14 Billion USD ( ₩1.69 Trillion KRW).
- NatureCell Co.Ltd (KQ:007390): Ranked #9400 globally with a market cap of $895.63 Million USD ( ₩1.32 Trillion KRW).
- Oscotec Inc (KQ:039200): Ranked #10937 globally with a market cap of $654.17 Million USD ( ₩965.30 Billion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #5752 | Sam Chun Dang Pharm. Co. Ltd | KQ:000250 | $2.26 Billion | ₩156100.00 |
| #8322 | ST Pharm Co.Ltd | KQ:237690 | $1.14 Billion | ₩90400.00 |
| #9400 | NatureCell Co.Ltd | KQ:007390 | $895.63 Million | ₩24900.00 |
| #10937 | Oscotec Inc | KQ:039200 | $654.17 Million | ₩34350.00 |
CrystalGenomics Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, CrystalGenomics Inc's market cap moved from $196.14 Million to $ 26.40 Million, with a yearly change of -15.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩26.40 Million | -35.24% |
| 2025 | ₩40.76 Million | -38.17% |
| 2024 | ₩65.93 Million | -13.33% |
| 2023 | ₩76.07 Million | -20.71% |
| 2022 | ₩95.95 Million | -47.13% |
| 2021 | ₩181.48 Million | -44.53% |
| 2020 | ₩327.14 Million | +20.95% |
| 2019 | ₩270.49 Million | -14.45% |
| 2018 | ₩316.18 Million | -3.62% |
| 2017 | ₩328.05 Million | +39.71% |
| 2016 | ₩234.81 Million | +19.72% |
| 2015 | ₩196.14 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of CrystalGenomics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $26.40 Million USD |
| MoneyControl | $26.40 Million USD |
| MarketWatch | $26.40 Million USD |
| marketcap.company | $26.40 Million USD |
| Reuters | $26.40 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About CrystalGenomics Inc
CrystalGenomics, Inc., a biopharmaceutical company, discovers and develops structural chemoproteiomics-based drugs in Korea. Its lead development candidate is NSAID (CG100649), which is a tissue specific anti-inflammatory agent with cardiovascular, gastrointestinal, and renal safety profiles that has completed Phase IIa clinical trial. The company's drug candidates also include CG200745, a histon… Read more